Drug Profile
Anti-cancer therapeutic - Amgen
Latest Information Update: 14 Feb 2024
Price :
$50
*
At a glance
- Originator Amgen
- Class Immunoconjugates; Maytansinoids; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 28 Dec 2018 No recent reports of development identified for phase-I development in Cancer in USA
- 17 Nov 2015 Phase-I clinical trials in Cancer in USA (unspecified route)